2025 Q4 -tulosraportti
Vain PDF
112 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·5 t sittenUSA-based banks/brokerages now up approx 4.2 mill shares on the shareholder list tonight combined, roughly calculated. Status from 2 days ago. Anyone else who can look at this??
Friday and yesterday the U.S. based companies had: 775.741 shares. Same as Thursday, and on 22.7.2026. And back to 1.7. The only one registered in usa is State Street Bank and Trust Company. The Bank of N.Y. Mellon is listed in 3 places but in Belgium. J. P. Morgan is in the UK. These 5 listings have as of today: 775.741 1.006.767 + 939.288 + 770.640 711.862 Sum 4.204.298 shares These 5 had on Friday: 3.952.777 JPM has since sold ~ 500.000 and BNYM increased. 1.7 they had in total 3,8 million pcs. That woke one up!- ·5 t sitten · MuokattuWhy did the message about the board change with Dinah Sah and the change of board authorization to 20% come exactly now on August 4, 2026?? Why such a rush right after the holiday with a board change??? Everything I've read today focuses on her professional research expertise. But is there something completely different that is actually behind it??? A small detail in her LinkedIn profile that I saw earlier today was that she has VC experience and expertise. Venture Capital, It just struck me now. Checked a bit. Vida Ventures. Specialist investor in the biotech sector. Approx 20 billion in assets under management. Makes approx 4 investments a year, size approx 500 million to 1 billion equity stakes for this normally approx 10 to 20%. Possibly together with a few others. They bring their people onto the board and possibly hire specialists. Who sits on the Advisory Board at Vida Ventures?? Dinah Sah. https://vidaventures.com/vida-team/ How big is the authorization the board is asking for, you said - up to 20%. 54 million new shares for 1 billion. Ok for me. I quietly think to myself that 1 billion more is now being raised for a 20% stake. Approx Mcap 5 billion will be the valuation. Specialist investors must pay a significant premium, is Wiklund said to have stated? Circio has changed ambitions. They want capital to acquire delivery technologies so that they can deliver a full package, not just circVec. That gives much higher value. They have touched upon the topic. Rocket mentioned it in a post earlier this evening. Changed strategy. Circio could become a much more valuable company in a short time, Circio wants to become something more and bigger. They have ambitions and are positioning the company in the midst of the large US bio capital, Ps Vida sold a portfolio company on May 3, 2026 for approx 22 billion. They have money for new investments. https://www.businesswire.com/news/home/20260503600344/en/Two-River-and-Vida-Ventures-Extend-Track-Record-of-Company-Creation-and-Value-Realization-Following-the-Candid-Therapeutics-Acquisition-by-UCBWhy renew a power of attorney of which much remained, both time and amount, less than 2 months after they fetched 300 million and a total gross of 620 million in 5 months?? ?????? Nice to have??? Or something urgent? Surely this isn't the power of attorney Wiklund has been lying on the beach thinking about during the holiday if there wasn't something current that triggered the thinking.
- ·8 t sittenWhat do you see as the potential price in a best-case scenario, if everything goes according to plan?
If everything goes according to plan, my personal best-case scenario is approximately: Preclinical acquisition: 60-120 NOK Acquisition after clinical validation: 110-250 NOK If Circio additionally succeeds in building a broader platform that combines circVec with its own IP in delivery: 400 NOK+, but then we are talking about a completely different company than what we see today and many more shares in the company. I still believe in 400 NOK ++ if this were to happen. To experience a best case scenario for the share price, an acquisition must occur. I don't believe the company will be valued higher than 30-60 kroner without an acquisition. This is, after all, Oslo Børs. For all we know, the price could remain between 10 and 20 kroner for a long time to come. - ·8 t sitten · MuokattuIs it just me, or does it seem like Circio has significantly raised its ambition level in recent months? After digesting today's announcements, I went through my own notes, previous interviews, stock exchange announcements, and statements from the CEO. There are several observations that become particularly interesting when viewed in context: 1) Circio has raised a total of 620 MNOK and communicated runway until at least 2030. 2) After the successful capital raise, the focus in communication has gradually shifted from preclinical data packages to clinical development, even though several important preclinical milestones remain. Why? 3) Today they are bringing in Dinah Sah, a strong RNA/AAV profile with experience in taking relevant programs from preclinical to clinical. 4) Under the warrant program, the CEO stated that the capital can also be used to acquire/buy complementary and relevant delivery technology, while the company wrote: "establishment of a state-of-the-art in vivo CAR-T delivery system." 5) Today they have announced that they want a renewed capital authorization to have flexibility towards specialized and institutional investors, even though they already have a strong capital base. Normally this is just a formality, but they could just as well have dropped specifying why they want a new capital authorization and instead given a general justification. Therefore, I have a question: Could it be that Circio has such good internal unpublished data, that the goal is no longer just to build a leading circRNA expression platform, but a broader platform that combines both expression and delivery? That would then explain why the company is already building its board, organization, and strategy for clinical development, long before we have seen the most important preclinical milestones and before primate studies have even been a central topic in communication. It also explains the change in wording, which has become much more aggressive with formulations like "leading global player", "state-of-the-art", "no direct competitors" and "platform engine". This is 100% speculation, and maybe I'm overinterpreting, but the sum of these observations makes me wonder if Circio is building something bigger than originally planned. If the ambition is to combine circVec with complementary delivery technology, they could theoretically develop a powerhouse in gene and cell therapy. Hmmm 🤔
Considered buying more tomorrow.. After reading the post I didn't get less excited 💪
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
112 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·5 t sittenUSA-based banks/brokerages now up approx 4.2 mill shares on the shareholder list tonight combined, roughly calculated. Status from 2 days ago. Anyone else who can look at this??Friday and yesterday the U.S. based companies had: 775.741 shares. Same as Thursday, and on 22.7.2026. And back to 1.7. The only one registered in usa is State Street Bank and Trust Company. The Bank of N.Y. Mellon is listed in 3 places but in Belgium. J. P. Morgan is in the UK. These 5 listings have as of today: 775.741 1.006.767 + 939.288 + 770.640 711.862 Sum 4.204.298 shares These 5 had on Friday: 3.952.777 JPM has since sold ~ 500.000 and BNYM increased. 1.7 they had in total 3,8 million pcs. That woke one up!
- ·5 t sitten · MuokattuWhy did the message about the board change with Dinah Sah and the change of board authorization to 20% come exactly now on August 4, 2026?? Why such a rush right after the holiday with a board change??? Everything I've read today focuses on her professional research expertise. But is there something completely different that is actually behind it??? A small detail in her LinkedIn profile that I saw earlier today was that she has VC experience and expertise. Venture Capital, It just struck me now. Checked a bit. Vida Ventures. Specialist investor in the biotech sector. Approx 20 billion in assets under management. Makes approx 4 investments a year, size approx 500 million to 1 billion equity stakes for this normally approx 10 to 20%. Possibly together with a few others. They bring their people onto the board and possibly hire specialists. Who sits on the Advisory Board at Vida Ventures?? Dinah Sah. https://vidaventures.com/vida-team/ How big is the authorization the board is asking for, you said - up to 20%. 54 million new shares for 1 billion. Ok for me. I quietly think to myself that 1 billion more is now being raised for a 20% stake. Approx Mcap 5 billion will be the valuation. Specialist investors must pay a significant premium, is Wiklund said to have stated? Circio has changed ambitions. They want capital to acquire delivery technologies so that they can deliver a full package, not just circVec. That gives much higher value. They have touched upon the topic. Rocket mentioned it in a post earlier this evening. Changed strategy. Circio could become a much more valuable company in a short time, Circio wants to become something more and bigger. They have ambitions and are positioning the company in the midst of the large US bio capital, Ps Vida sold a portfolio company on May 3, 2026 for approx 22 billion. They have money for new investments. https://www.businesswire.com/news/home/20260503600344/en/Two-River-and-Vida-Ventures-Extend-Track-Record-of-Company-Creation-and-Value-Realization-Following-the-Candid-Therapeutics-Acquisition-by-UCBWhy renew a power of attorney of which much remained, both time and amount, less than 2 months after they fetched 300 million and a total gross of 620 million in 5 months?? ?????? Nice to have??? Or something urgent? Surely this isn't the power of attorney Wiklund has been lying on the beach thinking about during the holiday if there wasn't something current that triggered the thinking.
- ·8 t sittenWhat do you see as the potential price in a best-case scenario, if everything goes according to plan?If everything goes according to plan, my personal best-case scenario is approximately: Preclinical acquisition: 60-120 NOK Acquisition after clinical validation: 110-250 NOK If Circio additionally succeeds in building a broader platform that combines circVec with its own IP in delivery: 400 NOK+, but then we are talking about a completely different company than what we see today and many more shares in the company. I still believe in 400 NOK ++ if this were to happen. To experience a best case scenario for the share price, an acquisition must occur. I don't believe the company will be valued higher than 30-60 kroner without an acquisition. This is, after all, Oslo Børs. For all we know, the price could remain between 10 and 20 kroner for a long time to come.
- ·8 t sitten · MuokattuIs it just me, or does it seem like Circio has significantly raised its ambition level in recent months? After digesting today's announcements, I went through my own notes, previous interviews, stock exchange announcements, and statements from the CEO. There are several observations that become particularly interesting when viewed in context: 1) Circio has raised a total of 620 MNOK and communicated runway until at least 2030. 2) After the successful capital raise, the focus in communication has gradually shifted from preclinical data packages to clinical development, even though several important preclinical milestones remain. Why? 3) Today they are bringing in Dinah Sah, a strong RNA/AAV profile with experience in taking relevant programs from preclinical to clinical. 4) Under the warrant program, the CEO stated that the capital can also be used to acquire/buy complementary and relevant delivery technology, while the company wrote: "establishment of a state-of-the-art in vivo CAR-T delivery system." 5) Today they have announced that they want a renewed capital authorization to have flexibility towards specialized and institutional investors, even though they already have a strong capital base. Normally this is just a formality, but they could just as well have dropped specifying why they want a new capital authorization and instead given a general justification. Therefore, I have a question: Could it be that Circio has such good internal unpublished data, that the goal is no longer just to build a leading circRNA expression platform, but a broader platform that combines both expression and delivery? That would then explain why the company is already building its board, organization, and strategy for clinical development, long before we have seen the most important preclinical milestones and before primate studies have even been a central topic in communication. It also explains the change in wording, which has become much more aggressive with formulations like "leading global player", "state-of-the-art", "no direct competitors" and "platform engine". This is 100% speculation, and maybe I'm overinterpreting, but the sum of these observations makes me wonder if Circio is building something bigger than originally planned. If the ambition is to combine circVec with complementary delivery technology, they could theoretically develop a powerhouse in gene and cell therapy. Hmmm 🤔Considered buying more tomorrow.. After reading the post I didn't get less excited 💪
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
112 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·5 t sittenUSA-based banks/brokerages now up approx 4.2 mill shares on the shareholder list tonight combined, roughly calculated. Status from 2 days ago. Anyone else who can look at this??Friday and yesterday the U.S. based companies had: 775.741 shares. Same as Thursday, and on 22.7.2026. And back to 1.7. The only one registered in usa is State Street Bank and Trust Company. The Bank of N.Y. Mellon is listed in 3 places but in Belgium. J. P. Morgan is in the UK. These 5 listings have as of today: 775.741 1.006.767 + 939.288 + 770.640 711.862 Sum 4.204.298 shares These 5 had on Friday: 3.952.777 JPM has since sold ~ 500.000 and BNYM increased. 1.7 they had in total 3,8 million pcs. That woke one up!
- ·5 t sitten · MuokattuWhy did the message about the board change with Dinah Sah and the change of board authorization to 20% come exactly now on August 4, 2026?? Why such a rush right after the holiday with a board change??? Everything I've read today focuses on her professional research expertise. But is there something completely different that is actually behind it??? A small detail in her LinkedIn profile that I saw earlier today was that she has VC experience and expertise. Venture Capital, It just struck me now. Checked a bit. Vida Ventures. Specialist investor in the biotech sector. Approx 20 billion in assets under management. Makes approx 4 investments a year, size approx 500 million to 1 billion equity stakes for this normally approx 10 to 20%. Possibly together with a few others. They bring their people onto the board and possibly hire specialists. Who sits on the Advisory Board at Vida Ventures?? Dinah Sah. https://vidaventures.com/vida-team/ How big is the authorization the board is asking for, you said - up to 20%. 54 million new shares for 1 billion. Ok for me. I quietly think to myself that 1 billion more is now being raised for a 20% stake. Approx Mcap 5 billion will be the valuation. Specialist investors must pay a significant premium, is Wiklund said to have stated? Circio has changed ambitions. They want capital to acquire delivery technologies so that they can deliver a full package, not just circVec. That gives much higher value. They have touched upon the topic. Rocket mentioned it in a post earlier this evening. Changed strategy. Circio could become a much more valuable company in a short time, Circio wants to become something more and bigger. They have ambitions and are positioning the company in the midst of the large US bio capital, Ps Vida sold a portfolio company on May 3, 2026 for approx 22 billion. They have money for new investments. https://www.businesswire.com/news/home/20260503600344/en/Two-River-and-Vida-Ventures-Extend-Track-Record-of-Company-Creation-and-Value-Realization-Following-the-Candid-Therapeutics-Acquisition-by-UCBWhy renew a power of attorney of which much remained, both time and amount, less than 2 months after they fetched 300 million and a total gross of 620 million in 5 months?? ?????? Nice to have??? Or something urgent? Surely this isn't the power of attorney Wiklund has been lying on the beach thinking about during the holiday if there wasn't something current that triggered the thinking.
- ·8 t sittenWhat do you see as the potential price in a best-case scenario, if everything goes according to plan?If everything goes according to plan, my personal best-case scenario is approximately: Preclinical acquisition: 60-120 NOK Acquisition after clinical validation: 110-250 NOK If Circio additionally succeeds in building a broader platform that combines circVec with its own IP in delivery: 400 NOK+, but then we are talking about a completely different company than what we see today and many more shares in the company. I still believe in 400 NOK ++ if this were to happen. To experience a best case scenario for the share price, an acquisition must occur. I don't believe the company will be valued higher than 30-60 kroner without an acquisition. This is, after all, Oslo Børs. For all we know, the price could remain between 10 and 20 kroner for a long time to come.
- ·8 t sitten · MuokattuIs it just me, or does it seem like Circio has significantly raised its ambition level in recent months? After digesting today's announcements, I went through my own notes, previous interviews, stock exchange announcements, and statements from the CEO. There are several observations that become particularly interesting when viewed in context: 1) Circio has raised a total of 620 MNOK and communicated runway until at least 2030. 2) After the successful capital raise, the focus in communication has gradually shifted from preclinical data packages to clinical development, even though several important preclinical milestones remain. Why? 3) Today they are bringing in Dinah Sah, a strong RNA/AAV profile with experience in taking relevant programs from preclinical to clinical. 4) Under the warrant program, the CEO stated that the capital can also be used to acquire/buy complementary and relevant delivery technology, while the company wrote: "establishment of a state-of-the-art in vivo CAR-T delivery system." 5) Today they have announced that they want a renewed capital authorization to have flexibility towards specialized and institutional investors, even though they already have a strong capital base. Normally this is just a formality, but they could just as well have dropped specifying why they want a new capital authorization and instead given a general justification. Therefore, I have a question: Could it be that Circio has such good internal unpublished data, that the goal is no longer just to build a leading circRNA expression platform, but a broader platform that combines both expression and delivery? That would then explain why the company is already building its board, organization, and strategy for clinical development, long before we have seen the most important preclinical milestones and before primate studies have even been a central topic in communication. It also explains the change in wording, which has become much more aggressive with formulations like "leading global player", "state-of-the-art", "no direct competitors" and "platform engine". This is 100% speculation, and maybe I'm overinterpreting, but the sum of these observations makes me wonder if Circio is building something bigger than originally planned. If the ambition is to combine circVec with complementary delivery technology, they could theoretically develop a powerhouse in gene and cell therapy. Hmmm 🤔Considered buying more tomorrow.. After reading the post I didn't get less excited 💪
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt